Business
HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy
BASKING RIDGE, N.J. & RAHWAY, N.J., August 27, 2025--HERTHENA-Breast04 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic HR+/HER2- Breast Cancer
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":10600,"height":1888,"url":"https://media.zenfs.com/en/business-wire.com/db31ade386ab8ada74e8990a7cc38e19"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/f854eHF_3KqkwZSII7ssNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/db31ade386ab8ada74e8990a7cc38e19","width":960,"height":171},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/8KczQOtu6WgYYb1pMDmBKQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00Mjg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/db31ade386ab8ada74e8990a7cc38e19","width":1200,"height":214}},"lazy":false},{"type":"text","content":"BASKING RIDGE, N.J. & RAHWAY, N.J., August 27, 2025--(BUSINESS WIRE)--The first patient has been dosed in the HERTHENA-Breast04 phase 3 trial evaluating the efficacy and safety of investigational patritumab deruxtecan (HER3-DXd) versus investigator’s choice of treatment in patients with unresectable locally advanced or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer with disease progression following endocrine and CDK4/6 inhibitor therapy in either the adjuvant or first-line metastatic settings.","length":558,"tagName":"p"},{"type":"text","content":"Patritumab deruxtecan is a specifically engineered HER3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being developed jointly by Daiichi Sankyo and Merck (known as MSD outside of the United States and Canada).","length":251,"tagName":"p"},{"type":"text","content":"While survival rates are high for those diagnosed with early-stage breast cancer, only about 30% of patients initially diagnosed with advanced disease or having metastatic progression are expected to live five years following diagnosis.1 Patients with HR positive, HER2 negative metastatic breast cancer experience poor outcomes if they progress following initial treatment, highlighting the need for additional options.2","length":421,"tagName":"p"},{"type":"text","content":""Despite significant development in the treatment landscape, HR positive, HER2 negative metastatic breast cancer is a highly complex and challenging disease with an overall poor prognosis," said Mark Rutstein, MD, He...